Literature DB >> 16120045

Feverfew: weeding out the root of leukaemia.

Monica L Guzman, Craig T Jordan.   

Abstract

Malignant stem cells are central to the pathogenesis and perpetuation of acute myelogenous leukaemia (AML). Despite their crucial role, standard chemotherapy often does not target these critical cells and, thus, the 'root' of leukaemic disease is not eradicated. To derive better therapies, unique molecular features of malignant stem cells have been characterised for AML and evaluated with regard to ablation of disease. In the course of such studies, the compound parthenolide, which is derived from the medicinal plant feverfew, has recently been shown to preferentially induce AML stem cells to undergo apoptosis. Importantly, parthenolide had no discernable effect on normal blood cells. Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120045     DOI: 10.1517/14712598.5.9.1147

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  14 in total

1.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

2.  Heterocyclic aminoparthenolide derivatives modulate G(2)-M cell cycle progression during Xenopus oocyte maturation.

Authors:  Venumadhav Janganati; Narsimha Reddy Penthala; Chad E Cragle; Angus M MacNicol; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-03-04       Impact factor: 2.823

3.  Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Authors:  Joshua N Kolev; Kristen M O'Dwyer; Craig T Jordan; Rudi Fasan
Journal:  ACS Chem Biol       Date:  2013-11-08       Impact factor: 5.100

4.  Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.

Authors:  Hanan Alwaseem; Benjamin J Frisch; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2017-08-08       Impact factor: 3.641

5.  Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression.

Authors:  Narsimha R Penthala; Shobanbabu Bommagani; Venumadhav Janganati; Kenzie B MacNicol; Chad E Cragle; Nikhil R Madadi; Linda L Hardy; Angus M MacNicol; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2014-08-07       Impact factor: 6.514

6.  Anti-cancer activity of carbamate derivatives of melampomagnolide B.

Authors:  Venumadhav Janganati; Narsimha Reddy Penthala; Nikhil Reddy Madadi; Zheng Chen; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-05-27       Impact factor: 2.823

Review 7.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

8.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.

Authors:  Jiangbing Zhou; Hao Zhang; Peihua Gu; Jining Bai; Joseph B Margolick; Ying Zhang
Journal:  Breast Cancer Res Treat       Date:  2007-10-27       Impact factor: 4.872

9.  Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.

Authors:  Brian T Kawasaki; Elaine M Hurt; Madhuri Kalathur; Maria Ana Duhagon; John A Milner; Young S Kim; William L Farrar
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

10.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.

Authors:  Duane C Hassane; Monica L Guzman; Cheryl Corbett; Xiaojie Li; Ramzi Abboud; Fay Young; Jane L Liesveld; Martin Carroll; Craig T Jordan
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.